New scan could light up hidden cancers
NCT ID NCT04746638
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed phase 1 study tested a new radioactive imaging agent called 99mTc-RM26 in 10 people with prostate or breast cancer. The goal was to see how the agent spreads in the body and whether it can help spot tumors using SPECT scans. Researchers also checked for safety and compared the results with standard imaging like CT or MRI.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Technetium-99m RM26 (99mTc-RM26)
- What this could lead to
- If successful, this imaging method could provide a new way to spot certain cancers, potentially improving diagnosis and treatment planning.
- What could go wrong
- This is a very early, small study with only 10 participants. It is designed to test safety and basic imaging ability, not to prove effectiveness. The results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
TomskNRMC
Tomsk, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a new tracer light up hidden prostate cancer?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could deep breaths before surgery ward off Post-Op confusion?
- Could ionized gas help fight breast cancer after surgery?